Table 5 Clinical outcomes.
Rivaroxaban (n = 35) | Standard therapy (n = 32) | Hazard Ratio (95% CI) | p – value | |
|---|---|---|---|---|
Efficacy outcome, n (%) | ||||
Recurrent DVT | 4 (11.4) | 4 (12.5) | 0.95 (0.24–3.79) | 0.94 |
Safety outcome, n (%) | ||||
Major or CRNMB* | 1 (2.9) | 3 (9.4) | 0.31 (0.03–2.96) | 0.31 |
- Major bleeding | 0 | 1 (3.1) | ||
- CRNMB | 1 (2.9) | 2 (6.2) | ||
Any bleeding | 3 (8.6) | 3 (9.4) | 0.94 (0.19–4.68) | 0.94 |
Adverse event | 16 (45.7) | 14 (43.7) | 1.03 (0.50–2.12) | 0.93 |
Non-compliance, n (%) | 0 | 2 (6.2) | — | 0.22 |
